PKU drug palynziq under the microscope: what it does to diet and brain
NCT ID NCT04404530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 45 people with PKU who are taking Palynziq to see how the drug changes their diet, brain health, and nutrition. Researchers will track protein intake and blood levels over time. The goal is to understand the full impact of Palynziq beyond just lowering phenylalanine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palynziq (pegvaliase)
- What this could lead to
- If successful, this study could reveal how Palynziq improves diet and brain health in PKU, pointing toward better management strategies.
- What could go wrong
- This is an observational study with only 45 participants, so results may not apply to everyone. It does not test the drug's safety or effectiveness directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital Georgia Clinical Research Center
RECRUITINGAtlanta, Georgia, 30322, United States
-
The Emory Clinic
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene infusion rewrite the fate of PKU?
- Newborn screening study aims to catch rare diseases at birth
- PKU Drug's nutritional impact under the microscope
- PKU diet in childhood may shape adult IQ, study finds
- New PKU drink passes small taste and tolerance test
- New PKU formula shows promise in managing blood levels